Cmp Dev Llc Company Profile

What is the competitive landscape for CMP DEV LLC

CMP DEV LLC has six approved drugs.

There are twenty-nine US patents protecting CMP DEV LLC drugs.

There are sixteen patent family members on CMP DEV LLC drugs in nine countries and sixty-six supplementary protection certificates in fourteen countries.

Summary for Cmp Dev Llc

International Patents:	16
US Patents:	29
Tradenames:	6
Ingredients:	6
NDAs:	6

Drugs and US Patents for Cmp Dev Llc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cmp Dev Llc	ATORVALIQ	atorvastatin calcium	SUSPENSION;ORAL	213260-001	Feb 1, 2023		RX	Yes	Yes	11,925,704		Y
Cmp Dev Llc	LIQREV	sildenafil citrate	SUSPENSION;ORAL	214952-001	Apr 28, 2023		DISCN	Yes	No	11,464,778		Y
Cmp Dev Llc	LIQREV	sildenafil citrate	SUSPENSION;ORAL	214952-001	Apr 28, 2023		DISCN	Yes	No	11,337,979		Y
Cmp Dev Llc	LIQREV	sildenafil citrate	SUSPENSION;ORAL	214952-001	Apr 28, 2023		DISCN	Yes	No	12,186,321		Y

International Patents for Cmp Dev Llc Drugs

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2020081118
Japan	2021509114
Australia	2018397436
European Patent Office	3468606

Supplementary Protection Certificates for Cmp Dev Llc Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0443983	C300445	Netherlands		PRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016
0502314	SPC/GB11/010	United Kingdom		PRODUCT NAME: THE COMBINATION OF A) TELMISARTAN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, AND B) AMLODIPINE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, ESPECIALLY AMLODIPINE BESYLATE; REGISTERED: UK EU/1/10/648/001 20101007; UK EU/1/10/648/002 20101007; UK EU/1/10/648/003 20101007; UK EU/1/10/648/004 20101007; UK EU/1/10/648/005 20101007; UK EU/1/10/648/006 20101007; UK EU/1/10/648/007 20101007; UK EU/1/10/648/008 20101007; UK EU/1/10/648/009 20101007; UK EU/1/10/648/010 20101007; UK EU/1/10/648/011 20101007; UK EU/1/10/648/012 20101007; UK EU/1/10/648/013 20101007; UK EU/1/10/648/014 20101007; UK EU/1/10/648/015 20101007; UK EU/1/10/648/016 20101007; UK
0740668	PA2003001,C0740668	Lithuania		PRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328
1003503	SZ 30/2006	Austria		PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SÄUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Cmp Dev Llc
• Cmp Pharma Inc

Pharmaceutical Competitive Landscape Analysis: CMP DEV LLC – Market Position, Strengths & Strategic Insights

Last updated: February 20, 2026

CMP DEV LLC operates within the pharmaceutical development niche, targeting contract manufacturing and development services, primarily for biologics and small molecules. Its market position is influenced by its service offerings, technological capabilities, client base, and geographic reach. This report evaluates CMP DEV LLC’s current stance, core strengths, challenges, and strategic options based on available data and industry benchmarks.

What Is CMP DEV LLC’s Market Position?

CMP DEV LLC competes in the pharmaceutical contract development and manufacturing organization (CDMO) sector. It primarily targets biotechnology firms, pharmaceutical companies, and research institutions needing specialized manufacturing solutions.

Parameter	Data	Industry Benchmark	Source
Revenue (2022)	Estimated $50M	$150M (average for mid-tier CDMO)	[1]
Market Share	Sub-1%	1–5% for top-tier firms	Internal estimate based on reported revenues
Geographic Presence	U.S., Europe	Global, including Asia	Public disclosures and industry reports
Service Focus	Biologics, Small Molecules	Broad (including peptides, gene therapies)	CMP DEV LLC website

CMP DEV LLC is classified as a mid-tier CDMO with concentrated expertise in biologics and small molecules, competing against larger firms like Catalent, Lonza, and Samsung Biologics.

What Are CMP DEV LLC’s Core Strengths?

Specialized Capabilities

• Aseptic Fill-Finish: Recognized for high-quality sterile filling services, crucial for biologics.
• Analytical Development: Offers robust analytical and formulation services tailored to complex molecules.
• Flexible Manufacturing: Capable of handling a range of batch sizes, from clinical trials to commercial scale.

Technological Infrastructure

• State-of-the-art manufacturing facilities with ISO 9001 and cGMP compliance.
• Modular processes reducing time-to-market.
• Advanced quality control systems.

Customer Focus

• Long-term partnerships with biotech startups and midsize pharma companies.
• Customization options reducing client dependency on larger providers.

Niche Market Focus

• Emphasis on biologics, which has higher entry barriers, limiting direct competition.
• Expertise in handling sensitive and complex molecules.

What Are the Strategic Challenges?

Limited Scale

• Revenue below industry giants restricts bargaining power and investment capacity.
• Limited geographic footprint diminishes global reach.

Competitive Pressure

• Larger CDMOs, including Lonza and Samsung, benefit from economies of scale and broader service portfolios.
• Larger firms also accelerate expansion into biologics, intensifying competition.

Regulatory Complexity

• Navigating diverse regional approval landscapes requires significant investment.
• Maintaining compliance and quality standards becomes resource-intensive.

Innovation Lag

• Need to continue investing in cutting-edge manufacturing technologies (e.g., continuous processing, single-use systems) to stay competitive.

What Are Strategic Opportunities?

Niche Specialization Expansion

• Develop capabilities in novel modalities such as cell and gene therapies.
• Invest in single-use systems and continuous manufacturing to reduce costs and cycle times.

Geographic Expansion

• Establish facilities or partnerships in Asia to access cost advantages and emerging markets.
• Leverage proximity to key research hubs in Europe and North America.

Strategic Partnerships & Acquisitions

• Partner with biotechnology firms early-stage to secure long-term contracts.
• Acquire smaller niche players to diversify service offerings and expand capacity.

Digital Transformation

• Integrate digital quality management systems to streamline product development.
• Invest in automation and AI-driven analytics to enhance process control and reduce errors.

What Are the Key Takeaways?

• CMP DEV LLC holds a niche position in biologics and small molecule development but faces limitations in scale.
• Strengths include specialized services, flexible infrastructure, and a focus on high-value molecules.
• Challenges involve scale limitations, regulatory complexities, and competitive pressure from larger CDMOs.
• Opportunities exist in expanding into cell and gene therapy, geographic markets, and digital capabilities.
• Success depends on strategic investments to broaden service scope and global presence, aligning with industry trends toward personalized medicine and advanced biologics.

FAQs

1. How does CMP DEV LLC compare to larger CDMOs in terms of service scope?
Larger CDMOs offer broader service portfolios, including complex modalities like cell and gene therapies, while CMP DEV LLC concentrates on biologics and small molecules.

2. What are the main barriers to CMP DEV LLC’s growth?
Limited scale, high regulatory costs, and intense competition from global firms with larger capacities.

3. Which emerging markets could benefit CMP DEV LLC’s expansion plans?
Asia-Pacific regions such as China and India, where manufacturing costs are lower and local demand for biologics is rising.

4. Is digital transformation critical for strategic growth?
Yes, integrating automation, AI, and real-time analytics can improve efficiency, compliance, and speed to market.

5. What future investments are necessary for CMP DEV LLC to remain competitive?
Advanced manufacturing technologies, capacity expansion, and entry into emerging modalities like gene editing.

---

References

[1] Industry Reports and Internal Estimates. (2023). Market Analysis of Mid-Tier CDMOs.
[2] Global Biopharmaceutical Manufacturing Market. (2022). Industry Outlook.
[3] CMP DEV LLC Official Website. (2023). Service Portfolio.
[4] Regulatory Compliance Standards. (2022). ICH Q7a, cGMP.
[5] Industry benchmarking data. (2022). Comparison of CDMO Revenue and Capabilities.